Today, after a successful phase 2 trial on a rare lung disease treatment, Arena Pharmaceuticals jumped almost 45% to just under $28. Should investors sell to lock in gains, or hold on? Todd Hagopian is taking profits, selling more than half of his ARNA position.
Today, after a successful phase 2 trial on a rare lung disease treatment, Arena Pharmaceuticals jumped almost 45% to just under $28. Should investors sell to lock in gains, or hold on? Todd Hagopian is taking profits, selling more than half of his ARNA position.
Share this Article
Recommended